According to the Zhitong Finance App, Chuangmei Pharmaceutical (02289.HK) announced interim results for the six months ended June 30, 2026. The group achieved operating income of 2,448 billion yuan, an increase of 13.6% year on year; net profit attributable to shareholders of the parent company was 225.56 million yuan, an increase of 3.76% year on year; basic and diluted earnings per share were 0.2088 yuan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.